Skip to main content
Advertisement
  • Neurology.org
  • Journals
    • Neurology
    • Clinical Practice
    • Education
    • Genetics
    • Neuroimmunology & Neuroinflammation
  • Online Sections
    • Neurology Video Journal Club
    • Diversity, Equity, & Inclusion (DEI)
    • Innovations in Care Delivery
    • Practice Buzz
    • Practice Current
    • Residents & Fellows
    • Without Borders
  • Collections
    • COVID-19
    • Disputes & Debates
    • Health Disparities
    • Infographics
    • Neurology Future Forecasting Series
    • Null Hypothesis
    • Patient Pages
    • Topics A-Z
    • Translations
  • Podcast
  • CME
  • About
    • About the Journals
    • Contact Us
    • Editorial Board
  • Authors
    • Submit New Manuscript
    • Submit Revised Manuscript
    • Author Center

Advanced Search

Main menu

  • Neurology.org
  • Journals
    • Neurology
    • Clinical Practice
    • Education
    • Genetics
    • Neuroimmunology & Neuroinflammation
  • Online Sections
    • Neurology Video Journal Club
    • Diversity, Equity, & Inclusion (DEI)
    • Innovations in Care Delivery
    • Practice Buzz
    • Practice Current
    • Residents & Fellows
    • Without Borders
  • Collections
    • COVID-19
    • Disputes & Debates
    • Health Disparities
    • Infographics
    • Neurology Future Forecasting Series
    • Null Hypothesis
    • Patient Pages
    • Topics A-Z
    • Translations
  • Podcast
  • CME
  • About
    • About the Journals
    • Contact Us
    • Editorial Board
  • Authors
    • Submit New Manuscript
    • Submit Revised Manuscript
    • Author Center
  • Home
  • Latest Articles
  • Current Issue
  • Past Issues
  • Neurology Video Journal Club
  • Residents & Fellows

User menu

  • Subscribe
  • My Alerts
  • Log in

Search

  • Advanced search
Neurology
Home
The most widely read and highly cited peer-reviewed neurology journal
  • Subscribe
  • My Alerts
  • Log in
Site Logo
  • Home
  • Latest Articles
  • Current Issue
  • Past Issues
  • Neurology Video Journal Club
  • Residents & Fellows

Share

April 14, 2020; 94 (15 Supplement) Friday, May 1

The Endocannabinoid 2-arachidonoylglycerol (2-AG) Is Elevated In Acute Ischemic Stroke (1352)

Marina Buciuc, Vlad C. Vasile, Gian Marco Conte, Eugene Scharf
First published April 14, 2020,
Marina Buciuc
1Neurology
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Vlad C. Vasile
2Laboratory Medicine & Pathology
3Cardiovascular Medicine
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Gian Marco Conte
4Radiology, Mayo Clinic
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Eugene Scharf
1Neurology
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Citation
The Endocannabinoid 2-arachidonoylglycerol (2-AG) Is Elevated In Acute Ischemic Stroke (1352)
Marina Buciuc, Vlad C. Vasile, Gian Marco Conte, Eugene Scharf
Neurology Apr 2020, 94 (15 Supplement) 1352;

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Permissions

Make Comment

See Comments

Downloads
0

Share

  • Article
  • Info & Disclosures
Loading

Abstract

Objective: To compare the venous plasma levels of endocannabinoids at different phases of acute ischemic stroke (AIS).

Background: Endocannabinoids, a family of bioactive lipids with widespread effects on vascular tone, inflammation, metabolism, and neurotransmission, are hypothesized to have anti-inflammatory and neuroprotective properties in their role as an acute phase response mechanisms during cerebral ischemia. Preclinical studies have demonstrated neuroprotective effects of endocannabinoids in acute cerebral ischemia and closed head injury. Therefore, the human endocannabinoid response to AIS warrants further investigation.

Design/Methods: We conducted an exploratory analysis of serial pooled venous endocannabinoid levels in patients with AIS or transient ischemic attack who presented to Mayo Clinic Hospital. The initial sample was collected within twelve hours of symptom onset (T1); the second sample was collected between 24 hours to 7 days after symptom onset (T2). The endocannabinoids N-arachidonoylethanolamine (AEA), 2-arachidonoylglycerol (2-AG), as well as palmitoylethanolamide (PEA) and oleoylethanolamide (OEA) were quantified by liquid chromatography mass spectrometry. The levels of the metabolites between T1 and T2 were compared via paired t-test.

Results: Fourteen patients met study criteria. Median (Q1/Q3 range): Age - 75 years (55 – 87); body mass index - 24.6 (22 – 35); National Institutes of Health Stroke Scale score (NIHSS) - 5 (4 – 15); infarct volume - 1.8 cm3 (0.4 – 6.8); T1- 9 hours (7 – 11); T2 -51 hours (43 – 58). Levels of 2-AG were significantly elevated at T2 compared to T1 with mean difference of 122.39 nM (95% CI: 26.91 – 217.88), p=0.0159. Levels of AEA, PEA and OEA did not differ between the two time points, p>0.05.

Conclusions: Circulating 2-AG increases significantly during the early phase of AIS. Further investigation with larger sample size is warranted to understand the precise role of 2-AG in the pathophysiology of acute cerebral ischemia and to determine whether modulation of this bioactive lipid holds promise as a neuroprotective treatment for acute stroke.

Disclosure: Dr. Buciuc has nothing to disclose. Dr. Vasile has nothing to disclose. Dr. Conte has nothing to disclose. Dr. Scharf has nothing to disclose.

Letters: Rapid online correspondence

No comments have been published for this article.
Comment

REQUIREMENTS

If you are uploading a letter concerning an article:
You must have updated your disclosures within six months: http://submit.neurology.org

Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.

If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.

Submission specifications:

  • Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
  • Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
  • Submit only on articles published within 6 months of issue date.
  • Do not be redundant. Read any comments already posted on the article prior to submission.
  • Submitted comments are subject to editing and editor review prior to posting.

More guidelines and information on Disputes & Debates

Compose Comment

More information about text formats

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.
Author Information
NOTE: The first author must also be the corresponding author of the comment.
First or given name, e.g. 'Peter'.
Your last, or family, name, e.g. 'MacMoody'.
Your email address, e.g. higgs-boson@gmail.com
Your role and/or occupation, e.g. 'Orthopedic Surgeon'.
Your organization or institution (if applicable), e.g. 'Royal Free Hospital'.
Publishing Agreement
NOTE: All authors, besides the first/corresponding author, must complete a separate Publishing Agreement Form and provide via email to the editorial office before comments can be posted.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

Vertical Tabs

You May Also be Interested in

Back to top
  • Article
  • Info & Disclosures
Advertisement

Use of Whole-Genome Sequencing for Mitochondrial Disease Diagnosis

Dr. Robert Pitceathly and Dr. William Macken

► Watch

Related Articles

  • No related articles found.

Alert Me

  • Alert me when eletters are published
Neurology: 100 (12)

Articles

  • Ahead of Print
  • Current Issue
  • Past Issues
  • Popular Articles
  • Translations

About

  • About the Journals
  • Ethics Policies
  • Editors & Editorial Board
  • Contact Us
  • Advertise

Submit

  • Author Center
  • Submit a Manuscript
  • Information for Reviewers
  • AAN Guidelines
  • Permissions

Subscribers

  • Subscribe
  • Activate a Subscription
  • Sign up for eAlerts
  • RSS Feed
Site Logo
  • Visit neurology Template on Facebook
  • Follow neurology Template on Twitter
  • Visit Neurology on YouTube
  • Neurology
  • Neurology: Clinical Practice
  • Neurology: Education
  • Neurology: Genetics
  • Neurology: Neuroimmunology & Neuroinflammation
  • AAN.com
  • AANnews
  • Continuum
  • Brain & Life
  • Neurology Today

Wolters Kluwer Logo

Neurology | Print ISSN:0028-3878
Online ISSN:1526-632X

© 2023 American Academy of Neurology

  • Privacy Policy
  • Feedback
  • Advertise